Mechanisms of postinfarct left ventricular remodeling

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 3, 2007, Pages 185-196

  French, Brent A ^a,b,c   Kramer, Christopher M ^b,c  

^a University of Virginia   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE; COLLAGEN; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; GLYCERYL TRINITRATE; HISTONE DEACETYLASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; MYOCYTE ENHANCER FACTOR 2; PHENYLEPHRINE; SCLEROPROTEIN; SIMVASTATIN; TACROLIMUS; TRANSCRIPTION FACTOR GATA 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BIOMECHANICS; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG BINDING SITE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART RUPTURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; LONGITUDINAL STUDY; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 47149111304     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.12.006     Document Type: Review

References (78)

1. Rosamond W., et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 100 (1999) 999-1008
3. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
4. Cohn J.N. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation 91 (1995) 2504-2507
5. Tiyyagura S.R., and Pinney S.P. Left ventricular remodeling after myocardial infarction: past, present, and future. Mount Sinai J. Med. 73 (2006) 840-851
6. Sutton M.G., and Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 (2000) 2981-2988
7. Lyne J.C., and Pennell D.J. Cardiovascular magnetic resonance in the quantitative assessment of left ventricular mass, volumes and contractile function. Coronary Artery Disease 16 (2005) 337-343
8. Judd R.M., et al. Technology insight: assessment of myocardial viability by delayed-enhancement magnetic resonance imaging. Nat. Clin. Pract. Cardiovasc. Med. 2 (2005) 150-158
9. Watzinger N., et al. The potential of contrast-enhanced magnetic resonance imaging for predicting left ventricular remodeling. J. Magn. Reson. Imaging 16 (2002) 633-640
10. Orn S., et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am. J. Cardiol. 99 (2007) 1109-1114
11. White H.D., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
12. Konstam M.A. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am. J. Cardiol. 96 (2005) 867-871
13. Yan R.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am. J. Cardiol. 96 (2005) 698-704
14. Mann D.L. Cardiac remodeling as therapeutic target: treating heart failure with cardiac support devices. Heart Failure Rev. 10 (2005) 93-94
15. Sharpe N. Pharmacologic effects on cardiac remodeling. Curr. Heart Failure Rep. 1 (2004) 9-13
16. Mancini D., and Burkhoff D. Mechanical device-based methods of managing and treating heart failure. Circulation 112 (2005) 438-448
17. Cheng A., et al. Passive ventricular constraint prevents transmural shear strain progression in left ventricle remodelling. Circulation 114 1 Suppl (2006) I79-I86
18. Fundaro P., and Fundaro C. Left ventricular remodelling and outcomes after surgery: pathophysiological insights for a modern surgical approach to ischaemic cardiomyopathy. J. Cardiovasc. Med. 7 (2006) 781-784
19. Doughty R.N., and White H.D. Carvedilol: use in chronic heart failure. Expert Rev. Cardiovasc. Therapy 5 (2007) 21-31
20. Kelley S.T., et al. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Circulation 99 (1999) 135-142
21. Ratcliffe M.B. Non-ischemic infarct extension: a new type of infarct enlargement and a potential therapeutic target. J. Am. Coll. Cardiol. 40 (2002) 1168-1171
22. Jackson B.M., et al. Extension of borderzone myocardium in postinfarction dilated cardiomyopathy. J. Am. Coll.Cardiol. 40 (2002) 1160-1167
23. Kramer C.M., et al. Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. J. Mol. Cell. Cardiol. 30 (1998) 1773-1778
24. Saeed M., et al. Scarred myocardium imposes additional burden on remote viable myocardium despite a reduction in the extent of area with late contrast MR enhancement. Eur. Radiol. 16 (2006) 827-836
25. Wollert K.C., and Drexler H. Cell-based therapy for heart failure. Curr. Opin. Cardiol. 21 (2006) 234-239
26. Boyle M.P., and Weisman H.F. Limitation of infarct expansion and ventricular remodeling by late reperfusion. Study of time course and mechanism in a rat model. Circulation 88 (1993) 2872-2883
27. Reimer K.A., et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 56 (1977) 786-794
28. Yang Z., et al. Serial contrast-enhanced MRI of myocardial infarction in mice early after reperfusion: importance of early treatment in strategies to control reperfusion injury. J. Cardiovasc. Magn. Reson. 5 (2003) 3-4
29. Ross A.J., et al. Serial MRI evaluation of cardiac structure and function in mice after reperfused myocardial infarction. Magn. Reson. Med. 47 (2002) 1158-1168
30. Sabbah H.N. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Failure Rev. 9 (2004) 91-97
31. Antman E.M., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). [see comment][erratum appears in J. Am. Coll. Cardiol. 2005 April 19;45(8):1376]. J. Am. Coll. Cardiol. 44 (2004) 671-719
32. Micari A., et al. Automated quantification of the spatial extent of perfusion defects and viability on myocardial contrast echocardiography. Journal of the American Society of Echocardiography 19 (2006) 379-385
33. Frangogiannis N.G. Targeting the inflammatory response in healing myocardial infarcts. Current Medicinal Chemistry 13 (2006) 1877-1893
34. Dobaczewski M., et al. Vascular mural cells in healing canine myocardial infarcts. J. Histochem. Cytochem. 52 (2004) 1019-1029
35. Jugdutt B.I. The dog model of left ventricular remodeling after myocardial infarction. Journal of Cardiac Failure 8 6 Suppl (2002) S472-S475
36. Jugdutt B.I. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Current Drug Targets - Cardiovascular & Haematological Disorders 3 (2003) 1-30
37. Jugdutt B.I., et al. Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. J. Am. Coll. Cardiol. 39 (2002) 1538-1545
38. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough?. Circulation 108 (2003) 1395-1403
39. Udelson J.E. Ventricular remodeling in heart failure and the effect of beta-blockade. Am. J. Cardiol. 93 (2004) 43B-48B
40. Hayashidani S., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol Heart Circulat. Physiol. 285 (2003) H1229-H1235
41. Rohde L.E., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
42. Lindsey M.L., et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105 (2002) 753-758
43. Leor J., et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation 114 1 Suppl (2006) I94-I100
44. Schwarz E.R., et al. A new model of ventricular plication: a suturing technique to decrease left ventricular dimensions, improve contractility, and attenuate ventricular remodeling after myocardial infarction in the rat heart. J. Cardiovasc. Pharmacol. Therapeut. 5 (2000) 41-49
45. Leor J., and Cohen S. Myocardial tissue engineering: creating a muscle patch for a wounded heart. Ann. N Y Acad. Sci. 1015 (2004) 312-319
46. Kramer C.M., et al. Regional differences in function within noninfarcted myocardium during left ventricular remodeling. Circulation 88 (1993) 1279-1288
47. Malhotra R., et al. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ. Res. 85 (1999) 137-146
48. Akasaka Y., et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Modern Pathol. 19 (2006) 588-598
49. Gilson W.D., et al. Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. J. Am. Coll. Cardiol. 50 (2007) 1799-1807
50. Goussev A., et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am. J. Physiol. 275 2 Pt 2 (1998) H626-H631
51. Kim Y.-K., et al. Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction. J. Cardiac Failure 9 (2003) 238-245
52. Kramer C.M., et al. Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodelling. Am. J. Physiol. 277 4 Pt 2 (1999) H1429-H1434
53. Kloner R.A., et al. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 57 (1978) 56-63
54. Mann D.L., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
55. Aoki K., et al. Therapeutic effect of caspase inhibitors in the prevention of apoptosis and reversal of chronic cerebral vasospasm. J. Clin. Neurosci. 9 (2002) 672-677
56. Frey N., et al. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
57. Yarbrough W.M., et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 108 (2003) 1753-1759
58. Oi S., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur. J. Pharmacol. 376 (1999) 139-148
59. Luo J.D., et al. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br. J. Pharmacol. 132 (2001) 159-164
60. Luo J.D., et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin. Exp. Pharmacol. Physiol. 26 (1999) 903-908
61. Laufs U., et al. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 66 (2006) 145-154
62. Liao J.K. Statin therapy for cardiac hypertrophy and heart failure. J. Invest. Med. 52 (2004) 248-253
63. Fraccarollo D., et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. 42 (2003) 1666-1673
64. Selvanayagam J.B., et al. Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. Circulation 109 (2004) 345-350
65. Hedstrom E., et al. Myocardial SPECT perfusion defect size compared to infarct size by delayed gadolinium-enhanced magnetic resonance imaging in patients with acute or chronic infarction. Clin. Physiol. Funct. Imaging 24 (2004) 380-386
66. Jackson B.M., et al. Borderzone geometry after acute myocardial infarction: a three-dimensional contrast enhanced echocardiographic study. Ann. Thoracic Surg. 80 (2005) 2250-2255
67. Lund G.K., et al. Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology 245 (2007) 95-102
68. Sosnovik D.E., et al. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 115 (2007) 1384-1391
69. Helm, P.A. et al. (2008) Molecular MRI of post-infarct myocardial scar in mice using a collagen-targeted contrast agent. Radiology, in press
70. Dhingra R., et al. Cross-sectional correlates of serum heat shock protein 70 in the community. Am. J. Hypertens. 19 (2006) 227-231
71. Jugdutt B.I., and Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 78 (1988) 906-919
72. Jugdutt B.I., and Humen D.P. Limitation of left ventricular hypertrophy and dysfunction by ACE inhibition after anterior Q-wave myocardial infarction. Cardiology 89 (1998) 283-290
73. Ali S.M., et al. Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Coronary Artery Disease 9 (1998) 815-821
74. Apple K.A., et al. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J. Cardiovasc. Pharmacol. 47 (2006) 228-235
75. Cheng Y., et al. Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure. J. Pharmacol. Exp. Therapeut. 321 (2007) 469-476
76. Enomoto Y., et al. Early ventricular restraint after myocardial infarction: extent of the wrap determines the outcome of remodeling. Ann. Thoracic Surg. 79 (2005) 881-887
77. Backlund T., et al. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc. Res. 57 (2003) 727-737
78. Mann D.L. Targeted anticytokine therapy and the failing heart. Am. J. Cardiol. 95 (2005) 9C-16C